The Acid Queen by Susannah Cahalan review – Timothy Leary's right hand woman
Of Timothy Leary, we know plenty. How, in the early 1960s, he gave LSD to his psychology students at Harvard, to the inmates of a maximum-security jail to see whether it would stop them reoffending, to artists such as Charlie Mingus and Allen Ginsberg to map how it expanded their creativity.
The Beatles' song Tomorrow Never Knows was based on his writings. Mick Jagger flew to Altamont in a helicopter with him. He had perma-smile good looks, evangelical patter and likened himself to Socrates and Galileo. He even had a Pied Piper invitation: 'Turn on, tune in, drop out'. No wonder Richard Nixon believed he was 'the most dangerous man in America'.
What of Rosemary Woodruff? She was the fourth of his five wives, helping take care of his children in the long wake of their mother's suicide. She buffed the branding of the self-styled 'wisest man of the 20th century'. She fitted him with a hearing aid and sewed his clothing. She helped write speeches and the books that made him a must-read for any would-be prankster or beatnik. In 1970, she aided his escape from prison after he had been landed with a 30-year sentence for possessing drugs. She herself was forced underground for two decades. So much has been written about Leary, observes Susannah Cahalan: why so little about Woodruff?
Her life had been eventful long before she met the US's most notorious trip adviser. She was born in 1935 in St Louis, Missouri to a father – Victor the Magician – who performed card tricks at local taverns, and a mother who was an amateur cryptologist. Early on, Woodruff wanted out. She needed, she said, 'things to be grander than they were in my little neighbourhood, in my little home'. She decamped to New York, took amphetamines to ensure she was skinny enough to be hired as a stewardess for the Israeli airline El Al, and landed an uncredited role in a naval comedy called Operation Petticoat.
Woodruff was looking for otherness. She read Antonin Artaud and science fiction, explored theosophy, smoked cannabis and hung out at jazz clubs. She married a Dutch accordionist who yelled at and cheated on her; then a tenor saxophonist who, when he wasn't shooting up, beat her and cheated, too. 'I subscribed to 'the genius and the goddess paradigm',' she later reflected. 'I wanted genius men.' She met Leary at a gallery and was taken by his talk of 'audio-olfactory-visual alternations of consciousness'. They shared a ride to a psychedelic commune he'd established in upstate New York. What did she hope to find there, he asked. 'Sensual enjoyment and mental excitement.' 'What else?' 'To love. You, I suppose.'
The following years are the stuff of legend. Leary titillated and horrified the US in equal measure, telling Playboy readers that women would have hundreds of orgasms during sex on LSD, and claiming that the drug would 'blacken' white people so that they could pursue 'a pagan life of natural fleshly pleasure'. When he ran for the governorship of California against an actor called Ronald Reagan, Woodruff devised the campaign slogan: 'Come together, join the party'. Lauded for her cheekbones and elegance, she fed the press zingy one-liners, and was, says Cahalan, 'a natural high priestess'.
Does this add up to the greatness that Cahalan believes Woodruff sublimated during her life with Leary? Cahalan describes him as a 'so-called psychedelic guru' and 'a sweet-talking snake charmer'. Does that make her heroine a gull? Cahalan astutely observes that, for much of the 1960s, 'women were confidantes, calming tethers for the men to embark on frightening journeys into the psychic unknown'. In practice this meant, even when they were on the run, Woodruff ensured Leary never lacked for smoked oysters and fine wines.
Like the children of many LSD proselytisers, Leary's son, Jack, got high at a young age. Home life was chaotic. He was so hungry and tired by the time he got to school that he could barely read the blackboard. Meanwhile, Leary's daughter, Susan, taunted Woodruff for being 'frigid and barren', and played Donovan's Season of the Witch at maximum volume for hours on end. Diagnosed with schizophrenia, she later killed herself in jail while awaiting trial on charges of shooting her sleeping boyfriend in the head. This is what Yippies co-founder Abbie Hoffman meant when he told Leary: 'Your peace-and-love bullshit is leading youth down the garden path of fascism … ripe for annihilation.'
Biographies of lesser-known figures often end up high on their own supply. Their subjects are reappraised as radical, transformative, historical missing links. Cahalan is pleasingly sharp and satiric. She characterises some of Leary's extended circle as 'people who belittled their maids, fed their tiny dogs with silverware, and complained of the cost of shipping priceless art overseas'. Was Leary a visionary who foresaw today's boom in microdosing? 'Psychedelics have become too big not to fail,' Cahalan writes. 'The twin issues that helped curtail the study of these substances in the 1960s are back: evangelism and hubris.'
Woodruff and Leary divorced in 1976, but her later life was far from boring. Travelling on a 'World Passport', a document created by peace activists, she zigzagged through Afghanistan where she used a burqa to hide contraband; travelled to Catania where she met a count and 'made love in a secret grotto by a waterfall, drank grape brandy, and helped raise chickens'; to Colombia where she had encounters with venomous spiders and drug cartels. For many years she lay low in the US, lacking social security or health insurance, 'an exile in her native land'. Only in 1994 was she able to emerge from hiding. While she never did publish the memoir she'd been working on for many years, The Acid Queen is a fond, imaginatively researched tribute to her free, forever-seeking spirit.
The Acid Queen: The Psychedelic Life and Counterculture Rebellion of Rosemary Woodruff Leary by Susannah Cahalan is published by Canongate (£22). To support the Guardian, order your copy at guardianbookshop.com. Delivery charges may apply.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
27 minutes ago
- Medical News Today
Rapamycin may extend lifespan as effectively as dietary restrictions
Research is ongoing about potential strategies to prolong life. A meta-analysis found that the drug rapamycin prolongs life in several vertebrate appeared to prolong life at a level similar to dietary restrictions. How to prolong life is a key area of scientific research. Experts are interested in medications that have the potential to boost longevity.A recent meta-analysis published in Aging Cell explored how rapamycin and metformin influenced longevity among several results confirmed that dietary restriction appears to prolong life and that rapamycin offers similar benefits. Researchers also found that metformin did not seem to prolong life. More research is required to see how rapamycin might help boost longevity in people. Rapamycin: Does it increase lifespan?In this paper, researchers note that decreasing food intake without malnourishment appears to prolong life but that this strategy is difficult for people to stick to. Thus, looking into possible medications that produce similar effects is an area of research. The two medications that were the focus of this analysis were rapamycin and metformin. According to the National Cancer Institute, rapamycin has a few functions, such as being an immunosuppressant and antibiotic, and it can help people who get helps with type 2 diabetes management. This analysis involved a systematic literature search to find relevant data. The final analysis included data from 167 papers looking at eight total vertebrate species, seeking to see how both medications affected longevity and how they compared to dietary extracted information on average and median lifespan from the papers. For this analysis, the two types of dietary restriction were caloric reduction and fasting, and researchers also sought to see if the results differed based on the sex of the animals involved. The data came from animals like mice, rats, turquoise killifish, and rhesus macaques. Overall, there were more males studied than females. There was also the most data on dietary restriction, and the most common type of dietary restriction was decreasing the number of calories. Regarding dietary restriction, the findings suggested great variation regarding the effects. Overall, researchers found that dietary restriction and rapamycin had a similar impact and appeared to contribute to prolonged life. Metformin appeared to only have a minimal impact on life from one metformin model, there appeared to be no consistent differences between male and female animals regarding longevity. Study author Zahida Sultanova, PhD, a Leverhulme Early Career Research Fellow with the University of East Anglia, in the United Kingdom summarized the key findings of the study to Medical News Today: 'We checked whether the two best-known 'diet-mimic' drugs increase lifespan similar to eating less in animals. By pooling data from 167 studies, we found that rapamycin is almost as reliable as eating less for increasing lifespan, whereas metformin is not. In other words, a compound that was extracted from soil bacteria 50 years ago seems able to copy many of the biological effects of a permanent diet, at least in lab animals.'Do the same benefits apply to people?This research analyzed animal data but did not include data about people. Additionally, most of these studies involved these animals in a laboratory setting and only looked at a small number of meta-analysis was also the work of only three researchers, sometimes with only one researcher doing a component of the work, which could have impacted the had the least amount of data on metformin, so more research about this medication might be helpful. They also operated under the assumption that if a paper did not specify male or female subjects, it was a mixed group, which could have been incorrect. The authors further note that the 'results were sensitive to how lifespan was reported.' Researchers also acknowledge strong publication bias and a lot of heterogeneity. Additionally, the type of measure used in study reporting affected results. In one measurement, the impact on life extension disappeared for the most part, the authors did not find a consistent difference in results based on the sex of the animals. They explain this could be because of 'differences in taxonomic groups studied […] and the calculated effect size.' Sultanova noted the following cautions regarding the findings: 'This study includes a high number of scientific studies conducted on different organisms such as mice, fish and monkeys. However, survival results in humans are not included because these drugs were not tested in humans for lifespan extension. Even if they are, the studies will take a long time considering the length of human lifespan. So, we do not recommend people to take rapamycin before the results of human trials consistently show that there are no side effects.'Why is it hard to study rapamycin in humans?Researchers suggest the need for research involving other species in natural and laboratory settings. They also note the need to understand the difference in impact for 'different strains of the same species exposed to the same treatment.'Future research can further focus on the differences between rapamycin and metformin and why they impact lifespan differently. More research into the differences in rapamycin's results in males and females could be helpful as well. More research can be done to see if rapamycin can promote prolonged life in people, but there may be some challenges in this Ali, MD, a board-certified general surgeon, bariatric surgeon, and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in the study, told MNT that it 'shows the contribution of the immune system to lifespan, as rapamycin is an immunosuppressive medication.'According to him: 'The most logical next step is to explore the findings in humans; however, this would be a difficult study to design as rapamycin is a medication used in specific cancers and organ transplant and has significant side effects.'Despite this, the results show a potential benefit of rapamycin that warrants more explained that: 'Clinically, that puts rapamycin (and the mTOR pathway it targets) at the front of the queue for future anti-ageing therapies in humans. The compound had already been used for organ-transplant patients, so medical professionals understand its potential side effects.''The next step is waiting for the results of ongoing human trials that test lower and intermittent doses of rapamycin and refining the compound to 'rapalog' versions that keep the benefits while omitting side-effects such as immune suppression,' she told us.'Another important next step would be developing drugs that are similar in structure and function to rapamycin but without the side-effects. Scientists have already started refining rapamycin and producing the so-called rapalogs,' Sultanova noted.
The Independent
28 minutes ago
- The Independent
Princess Lilibet stars in Meghan's teaser video for As Ever brand relaunch
The Duchess of Sussex has shared new footage of her and her daughter Lilibet in their family's Montecito garden whilst teasing her As Ever brand relaunch on Monday (23 June). In a clip posted on Instagram, Meghan can be seen in the garden scouring ingredients for her products, such as an apricot spread. The four-year-old was filmed walking over a bridge hand-in-hand with her mother in their home. 'A little behind the scenes of @aseverofficial', Meghan wrote, 'Hope you enjoy your treats when they arrive this week!' As Ever's re-launch last Friday introduced two new products, a $28 limited-edition orange blossom honey and a $9 apricot spread.
Telegraph
30 minutes ago
- Telegraph
Trump comes, not to bury Nato, but to save it
This week Nato will mark its first 76 years at its summit in The Hague. All eyes will be on Donald Trump and his robust 'America First' approach on the world stage, which has already involved the use of decisive military force against Iran's nuclear facilities. The US president has been a firm critic of Nato, but has also been responsible for a dramatic revival of the alliance. Trump has made it clear that Nato's survival depends on America's fellow members stepping up to fully participate in burden sharing with the US. The Russians have clearly viewed Nato as weak and divided and are increasingly willing to test its resolve. The US presidency must apply concerted pressure on America's allies to do far more to foster partnership rather than dependency, especially as the United States must increasingly focus on the immense threat in the Indo-Pacific presented by Communist China. In 2024, only 22 Nato members spent the 2 per cent of GDP on defence agreed to by the alliance in 2014. This is unacceptable. It leaves the alliance dangerously vulnerable when it should be projecting strength and resolve. Countries that spent less than 2 per cent of real GDP on defence last year included Italy (1.5 per cent), Canada (1.4 per cent), Spain (1.3 per cent), and Belgium (1.3 per cent). In contrast, Poland (4.1 per cent), Estonia (3.4 per cent), Latvia (3.2 per cent), and Greece (3.1 per cent) all spent above 3 per cent of GDP. Justin Trudeau's now departed Canadian government was among the very worst Nato slackers, consistently underinvesting in Canada's military with shockingly low figures for a nation with the 10 th largest GDP in the world. His successor as prime minister, Mark Carney, has vowed to raise Canadian defence spending to 2 per cent, but this is simply not enough. Ottawa needs to be serious about Nato's mission, and playing a full part in the alliance in the coming decades. As Heritage Foundation research has shown, 'European Nato members have collectively underfunded their own defence by $827.91 billion since 2014 – nearly equal to the entire annual US defence budget.' This is a staggering figure – a damning indictment of a culture of complacency and dependency in many Nato allies over the past decade. Not only should every Nato member immediately invest the minimum agreed level of spending on their own defence, they should also commit to matching the current US level of 3.5 per cent of GDP, and pledge to reach 5 per cent of GDP, which is expected to be the new benchmark set at the forthcoming Nato summit according to Nato Secretary General Mark Rutte. President Trump's pressure on Nato partners to spend more on defence is already having a major impact. After decades of reckless underinvestment, Germany, the world's fourth-largest economy and the biggest in Europe, has announced plans for a dramatic increase in defence spending, and has accepted in principle that German spending must eventually rise to 5 per cent of GDP if it is serious about defending its own borders from a potential attack by Russia. France, which has barely reached the agreed minimum 2 per cent of GDP on defence in recent years, has announced that it will push European defence spending levels to 3-3.5 per cent of GDP ahead of the Hague summit. Even Belgium, one of Nato's most lacklustre members, has declared it will boost defence spending to 3.5 per cent of GDP. The UK has just announced a $20 billion investment in its nuclear warhead programme, and the construction of 12 nuclear-powered attack submarines, as part of its new Strategic Defence Review, released this month. The Baltic States and Poland are already building on their robust records by pledging significant further increases in the years ahead. Poland will spend 4.7 per cent of GDP on defence this year, while Estonia has committed to spending 5.4 per cent through until 2029. Lithuania will spend 5-6 per cent on defence from 2026 to 2030, and Latvia will spend 5 per cent by 2026. The positive developments in Europe should be warmly welcomed in Washington. In just the first few months of his presidency, Donald Trump has already significantly strengthened Nato. President Trump is not the alliance's destroyer, as his critics have alleged, but is in fact its saviour. Previous US presidents had urged European allies to do more, but their entreaties fell on deaf ears. It took the no-nonsense straight talk of Donald Trump to make European leaders sit up and take notice. In many ways the Trump presidency has been the antithesis of the weak-kneed Biden presidency. The humiliating debacle of Biden's reckless Afghanistan withdrawal would not have happened under Donald Trump, and nor would Russia's reckless invasion of Ukraine. With bold US leadership at the helm, Nato still has the vision, capacity and energy to thrive and prosper for another 76 years. American exceptionalism is the most powerful force for liberty in the world today. It is greatly strengthened by America's alliances with key partners, and Nato is at the very heart of the transatlantic partnership.
